Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Bio Essence (BIOE) Total Current Liabilities (2020 - 2025)

Historic Total Current Liabilities for Bio Essence (BIOE) over the last 6 years, with Q3 2025 value amounting to $3.2 million.

  • Bio Essence's Total Current Liabilities rose 531.64% to $3.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.2 million, marking a year-over-year increase of 531.64%. This contributed to the annual value of $2.8 million for FY2024, which is 1437.46% up from last year.
  • According to the latest figures from Q3 2025, Bio Essence's Total Current Liabilities is $3.2 million, which was up 531.64% from $3.1 million recorded in Q2 2025.
  • Over the past 5 years, Bio Essence's Total Current Liabilities peaked at $3.8 million during Q1 2023, and registered a low of $1.5 million during Q2 2023.
  • Moreover, its 5-year median value for Total Current Liabilities was $3.1 million (2024), whereas its average is $2.9 million.
  • Per our database at Business Quant, Bio Essence's Total Current Liabilities crashed by 5252.64% in 2023 and then skyrocketed by 10420.15% in 2024.
  • Bio Essence's Total Current Liabilities (Quarter) stood at $2.8 million in 2021, then rose by 29.1% to $3.6 million in 2022, then plummeted by 31.12% to $2.5 million in 2023, then rose by 14.37% to $2.8 million in 2024, then increased by 15.25% to $3.2 million in 2025.
  • Its Total Current Liabilities was $3.2 million in Q3 2025, compared to $3.1 million in Q2 2025 and $3.2 million in Q1 2025.